Advertisement

Treatment of hepatocellular carcinoma: A summary of 33 years’ experience

  • Zhao-You Tang
  • Ye-Qin Yu
  • Xin-Da Zhou
  • Bing-Hui Yang
  • Ji-Zhen Lu
  • Zhi-Ying Lin
  • Zeng-Chen Ma
  • Sheng-Long Ye
  • Kang-Da Liu
  • Zhu-Yuan Yu

Abstract

Hepatocellular carcinoma (HCC), the most common type (90-95%) of primary liver cancer (PLC), causes 100,000 deaths every year in China. However, based on various strategies aimed at controlling this neoplasm, HCC has become “partly curable” instead of “incurable.” In China, hepatectomy for HCC started in the 1950s, liver cancer cell lines were established in the 1960s, field work in high risk areas, including epidemiology, etiology, and screening, have been conducted from the 1970s [1,2], and small HCC resection became an important clinical feature in the 1970s and 1980s [3–7]. During the past ten years, substantial progress has been made in the field of basic liver cancer research, studies have focused on the relation between hepatitis B virus (HBV) and HCC, a set of protooncogenes and HCC-related genes have been studied, and cytoreduction and sequential resection for unresectable HCC have become new trends [8].

Keywords

Transcatheter Arterial Embol Primary Liver Cancer Stage Resection Hepatic Arterial Infusion Chemotherapy Hepatic Artery Ligation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tang ZY (1986) Progress in liver cancer research in China. In: Editorial Committee of Current Medicine in China (eds) Current Medicine in China. People’s Medical Publishing House, Beijing, pp 353–360Google Scholar
  2. 2.
    Tang ZY, Wu MC, Xia SS (eds) (1989) Primary liver cancer. China Acad Publishers, Beijing; Springer, Berlin, pp 1–495Google Scholar
  3. 3.
    Tang ZY, Yu YQ, Lin ZY, Zhou XD, Yang BH, Cao YZ, Lu JZ, Tang CL (1979) Small hepatocellular carcinoma: Clinical analysis of 30 cases. Chin Med J 59: 35–40Google Scholar
  4. 4.
    Shanghai Coordinating Group for Research on Liver Cancer (Tang ZY, Yu EX, Wu CE, Gu XY) (1979) Diagnosis and treatment of primary hepatocellular carcinoma in the early stages: A report of 134 cases. Chin Med J 92: 801–806Google Scholar
  5. 5.
    Tang ZY (1980) Screening and early treatment of primary liver cancer with special reference to eastern China. Ann Acad Med Singapore 9: 234–239PubMedGoogle Scholar
  6. 6.
    Tang ZY, Ying YY, Gu TJ (1982) Hepatocellular carcinoma: Changing concepts in recent years. In: Popper H, Schaffner F (eds) Progress in liver diseases, vol VII. Grune and Stratton, New York, pp 637–647Google Scholar
  7. 7.
    Tang ZY (ed) (1985) Subclinical hepatocellular carcinoma. China Acad Publishers, Beijing;Springer, Berlin, pp 1–366Google Scholar
  8. 8.
    Tang ZY (ed) (1991) Advances in liver cancer and hepatitis research: 1991 Shanghai International Symposium on liver cancer and hepatitis. Shanghai Medical University Press, Shanghai, pp 1–162Google Scholar
  9. 9.
    Tang ZY, Yu YQ, Zhou XD (1986) The changing role of surgery in the treatment of primary liver cancer. Semin Surg Oncol 2: 103–112PubMedCrossRefGoogle Scholar
  10. 10.
    Curutchet HP, Terz JJ, Kay S, Lawrence W (1971) Primary liver cancer. Surgery 70: 467–479PubMedGoogle Scholar
  11. 11.
    Zhou XD, Tang ZY, Yu YQ, Yang BH, Lin ZY, Lu JZ, Ma ZC, Tang CL (1989) Long-term survivors after resection for primary liver cancer. Clinical analysis of 19 patients surviving more than ten years. Cancer 63: 2201–2206PubMedCrossRefGoogle Scholar
  12. 12.
    Zhou XD, Tang ZY, Yu YQ, Ma ZC, Yang BH, Lu JZ, Lin ZY (1989) Hepatocellular carcinoma: Some aspects to improve long-term survival. J Surg Oncol 41: 256–262PubMedCrossRefGoogle Scholar
  13. 13.
    Zhou XD, Tang ZY, Yu YQ, Ma ZC, Yang BH, Lu JZ, Lin ZY, Tang CL (1991) Prognostic factors of primary liver cancer: A report of 83 patients surviving 5 years or more compared with 811 patients surviving less than 5 years. J Exp Clin Cancer Res 10: 81–86Google Scholar
  14. 14.
    Tang ZY, Yu YQ, Yang BH (1987) Subclinical hepatocellular carcinoma. In: Wagner G, Zhang YH (eds) Cancer of the liver, esophagus, and nasopharynx. Springer, Berlin, pp 64–72Google Scholar
  15. 15.
    Tang ZY (1987) Recent advances in the study of small hepatocellular carcinoma. In: Editorial committee of Current Medicine in China (ed) . People’s Medical Publishing House, Beijing, pp 136–146Google Scholar
  16. 16.
    Tang ZY (1987) Surgical treatment of subclinical cases of hepatocellular carcinoma. In: Okuda K, Ishak KG (eds) Neoplasms of the liver. Springer, Tokyo, pp 367–373Google Scholar
  17. 17.
    Tang ZY (1989) Small hepatocellular carcinoma. In: Tang ZY, Wu MC, Xia SS (eds) Primary liver cancer. China Acad Publishers, Beijing; Springer, Berlin, pp 191–203Google Scholar
  18. 18.
    Tang ZY, Yu YQ, Zhou XD, Ma ZC, Yang R, Lu JZ, Lin ZY, Yang BH (1989) Surgery of small hepatocellular carcinoma: Analysis of 144 cases. Cancer 64: 536–541PubMedCrossRefGoogle Scholar
  19. 19.
    Tang ZY, Yang BH, Tang CL, Yu YQ, Lin ZY, Weng HZ (1980) Evaluation of population screening for hepatocellular carcinoma. Chin Med J 93: 795–799PubMedGoogle Scholar
  20. 20.
    Tang ZY, Yang BH (1989) Further evaluation of alpha fetoprotein as tumor marker for hepatocellular carcinoma with special reference to subclinical cancer. In: Tang ZY, Wu MC, Xia SS (eds) Primary liver cancer. China Acad Publishers, Beijing; Springer, Berlin, pp 172–179Google Scholar
  21. 21.
    Chen SL, Zhao HY, Yuan AN, Tang ZY, Ma ZC (1991) Diagnostic value of Tc-99m PMT delayed hepatobiliary imaging in small hepatocellular carcinoma: An analysis of 62 cases (in Chinese). Chin J Oncol 13: 30–32Google Scholar
  22. 22.
    Yu YQ, Tang ZY, Zhou XD (1980) Experience in resection of small hepatocellular carcinoma. Chin Med J 93: 491–494PubMedGoogle Scholar
  23. 23.
    Tang ZY, Yu YQ, Zhou XD (1983) Surgical treatment of subclinical hepatocellular carcinoma (HCC) and its ultimate outcome: A comparative study of 74 cases of subclinical HCC and 229 cases of clinical HCC undergone surgery. J Exp Clin Cancer Res 3: 261–268Google Scholar
  24. 24.
    Tang ZY (1981) A new concept on the natural course of hepatocellular carcinoma. Chin Med J 94: 585–588PubMedGoogle Scholar
  25. 25.
    Tang ZY, Yu YQ, Zhou XD, Chen QM (1981) Factors influencing primary liver cancer resection survival rate. Chin Med J 94: 749–754PubMedGoogle Scholar
  26. 26.
    Yu YQ, Tang ZY, Ma ZC, Zhou XD, Lu JZ (1991) Resection of the primary liver cancer of the hepatic hilus. Cancer 67: 1322–1325PubMedCrossRefGoogle Scholar
  27. 27.
    Tang ZY (1984) An important approach to prolonging survival further after radical resection of AFP positive hepatocellular carcinoma. J Exp Clin Cancer Res 3: 359–366Google Scholar
  28. 28.
    Liang XH, Loncarevic IF, Tang ZY, Yu YQ, Zentgraf H, Schroder CH (1991) Resection of hepatocellular carcinoma: Oligocentric origin of recurrent and multinodular tumours. J Gastroenterol Hepatol 6: 77–88PubMedCrossRefGoogle Scholar
  29. 29.
    Tang ZY, Yu YQ (1986) Long-term survival of hepatocellular carcinoma with reference to the role 44. Treatment of HCC 441 of early resection, multioperation, and multimodality treatment. Gann Monogr Cancer Res 31: 185–190Google Scholar
  30. 30.
    Tang ZY, Yu YQ, Ma ZC, Yang R, Zhou XD, Liu KD, Lu JZ, Bao YM, Lin ZY, Yang BH (1989) Conversion of surgically verified unresectable to resectable hepatocellular carcinoma: A report of 26 patients with subsequent resection. Chin J Cancer Res 1: 41–47CrossRefGoogle Scholar
  31. 31.
    Tang ZY (1989) Conversion of nonresectable to resectable hepatocellular carcinoma. In: Editorial Committee of Current Medicine in China (ed) Current medicine in China. People’s Medical Publishing House, Beijing, pp 215–221Google Scholar
  32. 32.
    Tang ZY, Yu YQ, Zhou XD, Ma ZC, Lu JZ, Liu KD, Lin ZY, Yang BH, Fan Z, Hou Z, Zhang M (1991) Cytoreduction and sequential resection: A hope for unresectable primary liver cancer. J Surg Oncol 47: 27–31PubMedCrossRefGoogle Scholar
  33. 33.
    Zhou XD, Tang ZY, Yu YQ, Ma ZC (1988) Clinical evaluation of cryosurgery in the treatment of primary liver cancer: A report of 60 cases. Cancer 16: 1–4Google Scholar
  34. 34.
    Bao YM, Tang ZY, Liu KD, Ma ZC, Xue Q, Qin WL (1989) Radioimmunotherapy combined with chemotherapy and immunotherapy for nude mice bearing human hepatocellular carcinoma. Chin J Oncol 11: 245–247Google Scholar
  35. 35.
    Lin G, Wang JH, Gu ZM (1991) Hepatic arterial infusion chemotherapy and embolization for the treatment of liver cancer: Effects and some influential factors. In: Tang ZY (ed) Advances in liver cancer and hepatitis research. Shanghai Medical University Press, Shanghai, p 126Google Scholar
  36. 36.
    Xu DB, Zhou M, Yu YQ, Xu ZZ, Sheng L (1991) Preliminary results of percutaneous portal vein embolization and chemotherapy in the treatment of primary liver cancer. In: Tang ZY (ed) Advances in liver cancer and hepatitis research: 1991 Shanghai International Symposium on Liver Cancer and Hepatitis. Shanghai Medical University Press, Shanghai, p 129Google Scholar
  37. 37.
    Lu JZ, Tang ZY, Yu YQ (1991) Alternating chemotherapy and fractionated radiotherapy in the treatment of primary liver cancer. In: Tang ZY (ed) Advances in liver cancer and hepatitis research: 1991 Shanghai International Symposium on Liver Cancer and Hepatitis. Shanghai Medical University Press, Shanghai, p 142Google Scholar
  38. 38.
    Tang ZY, Liu KD, Guo YD, Ma ZC, Yu D, Yu ZY, Bao YM, Lu JZ, Lin ZY, Yu YQ, Zhou HY, Chen KJ, Qian F, Yuan AN, Wu ZM (1986) Tumor imaging and targeting therapy for hepatocellular carcinoma: Preliminary results of experimental and clinical studies. Chin Med J 99: 855–860PubMedGoogle Scholar
  39. 39.
    Tang ZY, Ma ZC (1989) Establishment of transplantable human hepatocellular carcinoma in nude mice and their use in studies of tumor markers and radioimmunodetection. In: Tang ZY, Wu MC, Xia SS (eds) Primary liver cancer. China Acad Publishers, Beijing; Springer, Berlin, pp 172–179Google Scholar
  40. 40.
    Tang ZY, Liu KD, Fan Z, Lu JZ, Hou Z, Zhang YJ, Bao YM, Yu ZY, Zhou D, Xia XL, Tang WY, Ma ZC, Lin ZY, Zhou XD, Yu YQ, Yang BH, Zhao HY, Yuan AN, Zhou YG (1991) Eight years’ studies on tumor imaging and targeting therapy for hepatocellular carcinoma. In: Tang ZY (ed) Advances in liver cancer and hepatitis research: 1991 Shanghai International Symposium on Liver Cancer and Hepatitis. Shanghai Medical University Press, Shanghai, pp 148–149Google Scholar
  41. 41.
    Liu KD, Tang ZY, Bao YM, Lu JZ, Qian F, Yuan AN, Zhao HY (1989) Radioimmunotherapy for hepatocellular carcinoma (HCC) using 1–131 anti HCC isoferritin IgG: Preliminary results of experimental and clinical studies. Int J Radiat Oncol Biol Phys 16: 319–323PubMedCrossRefGoogle Scholar
  42. 42.
    Tang ZY, Liu KD, Bao YM, Lu JZ, Yu YQ, Ma ZC, Zhou XD, Yang R, Gan YH, Lin ZY, Fan Z, Hou Z (1990) Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second look resection. Cancer 65: 211–215PubMedCrossRefGoogle Scholar
  43. 43.
    Lu JZ, Tang ZY, Zhao HY (1991) Transhepatic artery injection of 1–131 (or 1–125) labeled Lipiodol for treatment of primary liver cancer. In: Tang ZY (ed) Advances in liver cancer and hepatitis research. Shanghai Medical University Press, Shanghai, p 149–150Google Scholar

Copyright information

© Springer-Verlag Tokyo 1992

Authors and Affiliations

  • Zhao-You Tang
    • 1
  • Ye-Qin Yu
    • 1
  • Xin-Da Zhou
    • 1
  • Bing-Hui Yang
    • 1
  • Ji-Zhen Lu
    • 1
  • Zhi-Ying Lin
    • 1
  • Zeng-Chen Ma
    • 1
  • Sheng-Long Ye
    • 1
  • Kang-Da Liu
    • 1
  • Zhu-Yuan Yu
    • 1
  1. 1.Liver Cancer InstituteShanghai Medical UniversityShanghaiPeople’s Republic of China

Personalised recommendations